194 related articles for article (PubMed ID: 21789246)
1. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.
Huang L; Zhao S; Frasor JM; Dai Y
PLoS One; 2011; 6(7):e22274. PubMed ID: 21789246
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Stone A; Valdés-Mora F; Gee JM; Farrow L; McClelland RA; Fiegl H; Dutkowski C; McCloy RA; Sutherland RL; Musgrove EA; Nicholson RI
PLoS One; 2012; 7(7):e40466. PubMed ID: 22808167
[TBL] [Abstract][Full Text] [Related]
3. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
4. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA
Mol Cancer Ther; 2012 Jul; 11(7):1488-99. PubMed ID: 22564725
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells.
Cun J; Yang Q
Biomed Pharmacother; 2018 Nov; 107():117-128. PubMed ID: 30086458
[TBL] [Abstract][Full Text] [Related]
7. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
9. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
11. Identifying differentially expressed genes and screening small molecule drugs for lapatinib-resistance of breast cancer by a bioinformatics strategy.
Zhuo WL; Zhang L; Xie QC; Zhu B; Chen ZT
Asian Pac J Cancer Prev; 2014; 15(24):10847-53. PubMed ID: 25605188
[TBL] [Abstract][Full Text] [Related]
12. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
Kangaspeska S; Hultsch S; Jaiswal A; Edgren H; Mpindi JP; Eldfors S; Brück O; Aittokallio T; Kallioniemi O
BMC Cancer; 2016 Jul; 16():378. PubMed ID: 27378269
[TBL] [Abstract][Full Text] [Related]
13. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
14. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
[TBL] [Abstract][Full Text] [Related]
15. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
[TBL] [Abstract][Full Text] [Related]
17. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
[TBL] [Abstract][Full Text] [Related]
18. Genomic Understanding Reveals the Important Role of FGFR2 as Paeoniflorin Target for Circumventing Breast Cancer Resistance to Tamoxifen.
Wibowo MA; Nugroho EP; Hermawan A
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3949-3958. PubMed ID: 34967576
[TBL] [Abstract][Full Text] [Related]
19. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
[TBL] [Abstract][Full Text] [Related]
20. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]